Ciaran M Lee, Thomas J Cradick, Gang Bao  Molecular Therapy 

Slides:



Advertisements
Similar presentations
Molecular Therapy - Nucleic Acids
Advertisements

Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1
Figure 1. AsCpf1 and LbCpf1-mediated gene editing in human cells
Volume 22, Issue 7, Pages (July 2015)
Expanding the Biologist’s Toolkit with CRISPR-Cas9
Genome-editing Technologies for Gene and Cell Therapy
In vivo optimization of the tagging approach using the Act5C model locus and flow cytometry-based quantification of the Act5C-GFP tagging success. In vivo.
Figure 2 Use of CRISPR/Cas9 for genome editing
CRISPR/Cas9 Technology–Based Xenograft Tumors as Candidate Reference Materials for Multiple EML4-ALK Rearrangements Testing  Rongxue Peng, Rui Zhang,
Volume 54, Issue 1, Pages (April 2014)
Molecular Therapy - Nucleic Acids
Harnessing CRISPR–Cas systems for bacterial genome editing
Volume 9, Issue 3, Pages (November 2014)
CRISPR-Cas9-based Photoactivatable Transcription System
The CRISPR/Cas9 system.1 Clustered regularly interspaced palindromic repeats (CRISPR) refers to sequences in the bacterial genome. The CRISPR/Cas9 system.1.
Mouse Genome Engineering via CRISPR-Cas9 for Study of Immune Function
Luther Davis, Nancy Maizels  Cell Reports 
Molecular Therapy - Methods & Clinical Development
Volume 65, Issue 1, Pages (January 2017)
Volume 7, Issue 1, Pages (April 2014)
Target-Specific Precision of CRISPR-Mediated Genome Editing
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Single-Stranded DNA Cleavage by Divergent CRISPR-Cas9 Enzymes
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
Therapeutic editing of hepatocyte genome in vivo
USH2A Gene Editing Using the CRISPR System
The CRISPR/Cas9 system.1 Clustered regularly interspaced palindromic repeats (CRISPR) refers to sequences in the bacterial genome. The CRISPR/Cas9 system.1.
Joseph Bondy-Denomy, Alan R. Davidson  Trends in Microbiology 
Molecular Therapy - Nucleic Acids
Guide RNA Functional Modules Direct Cas9 Activity and Orthogonality
Volume 22, Issue 3, Pages e3 (September 2017)
Volume 164, Issue 1, Pages (January 2016)
RNA-Guided Genome Editing in Plants Using a CRISPR–Cas System
Dipali G. Sashital, Blake Wiedenheft, Jennifer A. Doudna 
Andrew R. Bassett, Charlotte Tibbit, Chris P. Ponting, Ji-Long Liu 
Xiaoyu Chen, Jin Liu, Josephine M. Janssen, Manuel A.F.V. Gonçalves 
Volume 154, Issue 6, Pages (September 2013)
Volume 153, Issue 4, Pages (May 2013)
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
Volume 14, Issue 6, Pages (February 2016)
Volume 63, Issue 4, Pages (August 2016)
Genome-editing Technologies for Gene and Cell Therapy
VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9
Gang Wang, Na Zhao, Ben Berkhout, Atze T Das  Molecular Therapy 
Volume 69, Issue 1, Pages e3 (January 2018)
GFP to BFP Conversion: A Versatile Assay for the Quantification of CRISPR/Cas9- mediated Genome Editing  Astrid Glaser, Bradley McColl, Jim Vadolas  Molecular.
Volume 10, Issue 2, Pages (February 2018)
Volume 11, Issue 6, Pages (May 2015)
Volume 25, Issue 1, Pages (January 2017)
Molecular Therapy - Methods & Clinical Development
A CRISPR Approach to Gene Targeting
Volume 153, Issue 4, Pages (May 2013)
Volume 15, Issue 3, Pages (April 2016)
Molecular Therapy - Nucleic Acids
Volume 23, Issue 3, Pages (March 2015)
Fiona T van den Berg, John J Rossi, Patrick Arbuthnot, Marc S Weinberg 
Volume 17, Issue 5, Pages (October 2016)
Targeted Deletion of an Entire Chromosome Using CRISPR/Cas9
Gene editing by CRISPR/Cas9 for gene inactivation and targeted sequence replacement. Gene editing by CRISPR/Cas9 for gene inactivation and targeted sequence.
Molecular Therapy - Methods & Clinical Development
Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9
Thomas J Cradick, Peng Qiu, Ciaran M Lee, Eli J Fine, Gang Bao 
Volume 24, Issue 11, Pages (November 2016)
Volume 26, Issue 11, Pages (November 2018)
Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off- target Effects in Genome Editing  Ciaran M Lee, Thomas J Cradick,
Fig. 1 Exon 44–deleted DMD patient iPSC-derived cardiomyocytes express dystrophin after CRISPR-Cas9–mediated genome editing. Exon 44–deleted DMD patient.
CRISPR Immunological Memory Requires a Host Factor for Specificity
Volume 10, Issue 2, Pages (February 2018)
Presentation transcript:

The Neisseria meningitidis CRISPR-Cas9 System Enables Specific Genome Editing in Mammalian Cells  Ciaran M Lee, Thomas J Cradick, Gang Bao  Molecular Therapy  Volume 24, Issue 3, Pages 645-654 (March 2016) DOI: 10.1038/mt.2016.8 Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Overview of the Nme CRISPR-Cas9 system. Outline of the expression systems and the predicted structures of the of the 2-RNA (a) and sgRNA (b) systems. (c) T7EI assay showing activity of the Nme 2-RNA system and the Nme sgRNA system at the IL2RG locus in HEK 293T cells. (d) Activity of gRNAs with different lengths. Bars represent the average cutting efficiency for each length and the cutting activity for each locus tested is represented as circles. Data for the Nme 2-RNA system (blue bars) is taken from T7EI assay data from 13 endogenous loci and the data for the Nme sgRNA system (red bars) is taken from T7EI assay data from 10 endogenous loci. All experiments were carried out in HEK293T cells. gRNA lengths that had activity levels that differed significantly from the highest active gRNA length at denoted by *. Significance was determined using a two-tailed t-test. P < 0.05 (e) Luciferase single-strand annealing (SSA) assays to investigate protospacer adjacent motif (PAM) recognition of Nme Cas9. All data from biological triplicates. The significance of 2-RNA activity levels (*) and sgRNA activity levels (†) were determined using a two-tailed t-test. P < 0.05 (f) Extrapolated PAM sequence preference of the Nme CRISPR-Cas9 systems with 2-RNA (top) and the Nme sgRNA (bottom) based on results from Luciferase SSA assays. Molecular Therapy 2016 24, 645-654DOI: (10.1038/mt.2016.8) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Comparison of mismatch tolerance between Nme and Spy CRISPR-Cas9 systems. (a) Schematic of the luciferase based single-strand annealing (SSA) assay used to determine gRNA specificity. Following successful cleavage of the target site by Cas9, the shaded homologous regions can recombine via SSA resulting in the restoration of the full length luciferase open reading frame and expression of luciferase. The level of luciferase expressed is measured by the amount of D-luciferin which is converted into oxyluciferin and light. The activity of gRNA variants containing mismatches (b), insertions (c), or deletions (d) are displayed as heatmaps based on relative single-strand annealing activity. The activity of all gRNA variants was normalized to the original guide sequence. gRNAs of 20, 21, and 23 nt were used for Spy sgRNA, Nme sgRNA, and Nme 2-RNA systems respectively. All data derived from biological triplicates. The sequences and raw data for all gRNA variants can be found in Supplementary Table S3. Molecular Therapy 2016 24, 645-654DOI: (10.1038/mt.2016.8) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 On-target activity of Nme and Spy CRISPR-Cas9 systems targeting endogenous loci in HEK293T cells. Both Nme and Spy gRNAs target overlapping protospacer sequences. Shown are cleavage activities of different CRISPR/Cas9 systems at eight genomic loci as measured using the T7EI assay. Data from biological replicates. For each locus both Nme Cas9 2-RNA and sgRNA gRNAs were compared to Spy Cas9. Nme 2-RNA gRNAs with significantly different values are denoted by † whereas Nme sgRNA gRNAs with significant differences in activity compared to Spy Cas9 are denoted by *. Statistical analysis was carried out for the gRNA length with the highest activity at each locus. P < 0.05. Molecular Therapy 2016 24, 645-654DOI: (10.1038/mt.2016.8) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Cleavage activity of Spy Cas9 at on- and off-target sites. Activity of Spy gRNAs targeting (a) DHFR, (b) F8, and (c) HPRT1 at both on-target and off-target sites. (d–f) The target sequence at each locus is underlined and mismatches are highlighted in red. Sequence reads contain indels typical of non-homologous end joining repair following Cas9 cleavage. Only sites where activity levels were above 0.1% (as assessed by illumina MiSeq) are shown. Error bars represent 95% confidence intervals and P values were obtained using Fisher's exact test, *P < 0.001. Molecular Therapy 2016 24, 645-654DOI: (10.1038/mt.2016.8) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions